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Hyperosmotic stress enhances cytotoxicity of SMAC
mimetics
Sebastian Bittner1, Gertrud Knoll1 and Martin Ehrenschwender*,1
Inhibitors of apoptosis (IAP) proteins contribute to cell death resistance in malignancies and emerged as promising targets in
cancer therapy. Currently, small molecules mimicking the IAP-antagonizing activity of endogenous second mitochondria-derived
activator of caspases (SMAC) are evaluated in phase 1/2 clinical trials. In cancer cells, SMAC mimetic (SM)-mediated IAP depletion
induces tumor necrosis factor (TNF) secretion and simultaneously sensitizes for TNF-induced cell death. However, tumor cells
lacking SM-induced autocrine TNF release survive and thus limit therapeutic efficacy. Here, we show that hyperosmotic stress
boosts SM cytotoxicity in human and murine cells through hypertonicity-induced upregulation of TNF with subsequent induction
of apoptosis and/or necroptosis. Hypertonicity allowed robust TNF-dependent killing in SM-treated human acute lymphoblastic
leukemia cells, which under isotonic conditions resisted SM treatment due to poor SM-induced TNF secretion. Mechanistically,
hypertonicity-triggered TNF release bypassed the dependency on SM-induced TNF production to execute SM cytotoxicity,
effectively reducing the role of SM to TNF-sensitizing, but not necessarily TNF-inducing agents. Perspectively, these findings could
extend the clinical application of SM.
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Imbalances in pro- and anti-apoptotic proteins disturb
cellular death pathways and allow tumor cells to escape
from chemotherapy-induced apoptosis. Newer therapeutic
approaches aim to reinstate the cell’s death machinery by
targeting the pro-survival BCL-2 family members or the
cellular inhibitor of apoptosis proteins (IAP) cIAP1, cIAP2
and X-linked IAP (XIAP). Mechanistically, XIAP blocks
apoptosis by direct caspase inhibition whereas cIAP1/2 shut
down cell death promoting activities of receptor-interacting
protein kinase-1 (RIPK1). Overexpression of IAP contributes
to the onset of cancer and drug resistance,1,2 which stimulated
the development of SMAC mimetics (SM): small IAP-binding
molecules mimicking the IAP-antagonizing activity of endo-
genous second mitochondria-derived activator of caspases
(SMAC). SM free caspases fromXIAP-mediated inhibition and
trigger degradation of cIAP1/2, which is death promoting in
two interdependent ways: it initiates autocrine secretion of
tumor necrosis factor (TNF) and concomitantly undermines
the function of cIAP1/2 to counteract TNF-induced TNF-
receptor 1 (TNFR1)-mediated cytotoxicity.3–7 Usually, TNFR1
activation first triggers formation of a receptor-associated
signaling complex (termed ‘complex I’). cIAP1/2-mediated
ubiquitination of complex I provides a scaffold for recruitment
of kinases activating the survival-promoting canonical nuclear
factor kappa B (NFκB)-pathway. SM abolish complex I
ubiquitination and facilitate its transition to a secondary
cytosolic complex (termed ’complex II’), which can induce
apoptotic and necroptotic cell death via caspase-8 and RIPK1/
RIPK3, respectively.8 How SM trigger TNF production is not
fully understood, but SM-mediated loss of cIAP1/2 impairs
constitutive ubiquitination and subsequent proteasomal
degradation of NFκB-interacting kinase (NIK). Increasing
NIK levels activate the non-canonical NFκB pathway and
transcription of downstream target genes such as TNF.3,4,9,10
Efficient killing by SM alone requires both autocrine TNF
secretion and TNFR1-mediated cytotoxicity.3–7 Cancer cells that
do not release TNF upon SM treatment are consequently
resistant even though SM-mediated IAP depletion sensitizes for
TNF-induced cell death. Combining SM with exogenously
added TNF could overcome this limitation, but is clinically
challenging due to the severe cardio-vascular side effects of the
cytokine. However, aside from SM-triggered activation of the
non-canonical NFκB pathway, a plethora of stimuli can induce
cellular TNF production.11 Here, we show that hyperosmotic
stress boostsSMcytotoxicity in human andmurine cells through
hypertonicity-induced upregulation of TNF with subsequent
initiation of apoptotic and/or necroptotic cell death. Human acute
lymphoblastic leukemia (ALL) cells resisted SM treatment
under isotonic conditions due to poor SM-induced TNF
secretion. Under hypertonic conditions, however, SM treatment
displayed a robust, TNF-dependent cytotoxicity.Mechanistically,
hypertonicity-triggered TNF secretion bypassed the depen-
dency on SM-triggered TNF production for SM cytotoxicity and
reduced the role of SM to TNF-sensitizers, but not necessarily
simultaneous TNF-inducers. Perspectively, our findings could
extend the clinical application of SM.
Results
Hyperosmotic stress and SM synergistically kill L929
cells in a TNF-involving manner. Addition of osmotically
active solutes that cannot diffuse across the cell membrane
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(e.g. NaCl or mannitol) generates an osmotic pressure
gradient between the intra- and extracellular space (hyper-
osmotic stress or hypertonicity). Hypertonicity generated by
supplementing the cell culture medium with 75 mM NaCl or
150 mM mannitol (both increasing osmolarity by 150 mOsm/l)
drastically increased cell death in L929 cells upon challenge
with the SM BV6, LCL161 and birinapant compared with
isotonic conditions (Figures 1a–f). Although NaCl alone
displayed no cytotoxic effect up to a concentration of
100 mM, a gradual increase of extracellular NaCl was suffi-
cient to robustly trigger cell death even when low (and under
isotonic conditions marginally toxic) concentrations of BV6
and LCL161 were used (Figures 1g and h, upper panel). This
pointed to a synergistic effect and was quantitatively
assessed by calculating a combination index (CI) for BV6
and LCL161 plus NaCl. Briefly, CI-values o1 indicate a
synergistic effect and decreasing CI-values correlate with
enhanced synergism of the two compounds.12 Synergism in
terms of cell death induction was observed for both, BV6 and
LCL161 with NaCl (Figures 1g and h, lower panel). Addition
of the TNF-neutralizing TNFR2-Fc fusion protein etanercept
attenuated, but (especially at high SM concentrations) not
fully abrogated SM cytotoxicity in the presence of NaCl
(Figures 2a and b). This is in line with the concept that beside
TNF-dependent TNFR1 activation3–6 IAP depletion can also
kill cells in a TNF-independent, RIPK1-involving manner.13,14
In L929 cells, RIPK1 kinase activity is required for both,
SM-triggered TNF release and TNF-mediated cell death.15–18
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Figure 1 Hyperosmotic stress and SMAC mimetics synergistically kill L929 cells. (a–c) L929 cells were treated with the indicated concentrations of the SMAC mimetics
(a) BV6, (b) LCL161 and (c) birinapant (Biri) in the presence and absence of 75 mM NaCl. (d–f) Cells were treated as above, but 150 mM mannitol was used instead of NaCl.
(g and h) Top panel: L929 cells were challenged with the indicated concentrations of NaCl in the presence and absence of (g) 2 μM BV6 or (h) 0.3 μM LCL161. Lower panel: For
each combination of SMAC mimetic plus NaCl, the corresponding combination index (CI) value was calculated. CI-valueso1 indicate a synergistic effect (see also the Materials
and Methods section). Shown are data points and mean± S.E.M. from three independent experiments. For calculation of CI-values, mean values from three independent
experiments were used. Biri, birinapant
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Pharmacological inhibition of RIPK1 using necrostatin-1
(Nec-1) expectedly abrogated cytotoxicity of BV6/NaCl
(Figure 2c). As the pan-caspase inhibitor zVAD-fmk itself
induces TNF release and TNF-dependent necroptosis in
L929 cells,15,19 birinapant/NaCl cytotoxicity was not reversed
by zVAD-fmk alone but required additional GSK’872-medi-
ated inhibition of necroptosis-promoting RIPK3 (Figure 2d).
Collectively, these data suggested that hypertonicity enhanced
SM-triggered apoptotic and/or necroptotic cell death in a TNF-
involving manner.
Hypertonicity boosts TNF-dependent apoptosis in SMAC
mimetic-treated human ALL cells. Several SM are cur-
rently evaluated in clinical trials and recently encouraging
results for SM-based therapies in human ALL have been
reported.20,21 In human ALL cells (REH) and rhabdomyosar-
coma cells (KYM-1), hypertonicity (established by addition of
50 mM NaCl or 100 mM mannitol to the cell culture medium)
enhanced BV6-, LCL161- and birinapant-mediated cytotoxi-
city compared with isotonic controls (Figures 3a–c, g and h).
Under isotonic conditions non-toxic concentrations of BV6,
LCL161 and birinapant were capable to robustly kill ALL cells
when the extracellular osmotic pressure was gradually
increased (Figures 3d–f, upper panel). Calculation of the
CI revealed valueso1, again indicating a synergistic mode of
action for SM/NaCl combinations (Figures 3d–f, lower panel).
Neutralizing TNF with etanercept significantly diminished
SM-related cytotoxicity, demonstrating that (like in L929 cells)
TNF was involved in SM-mediated killing of ALL cells
facing hyperosmotic stress (Figures 4a and b). Notably,
SM-triggered cell death can engage the apoptotic and/or
necroptotic pathway,22 but apoptosis was apparently the
predominant form of cell death in REH cells challenged with
SM plus NaCl, as seen by (a) detection of annexin-V and
7-AAD in flow cytometry (Figure 4c); (b) increase of SM-
triggered caspase-8 and caspase-3/-7 activation (Figures 4d
and e) and (c) almost full-blown rescue with the pan-caspase
inhibitor zVAD-fmk (Figure 4f). In sum, these data extended
our observations in L929 cells and suggested that hyperto-
nicity and SM acted synergistically in TNF-mediated killing of
human ALL cells.
SM and hypertonicity cooperate in TNF release. We next
evaluated the molecular mechanism underlying SM/NaCl
synergism. Apparently, TNF was the key mediator for SM
cytotoxicity under hypertonic conditions (Figures 2a, b, 4a
and b). In L929 cells, increase in BV6- and LCL161-induced
cell death under hypertonic conditions (Figures 1a and b) was
paralleled by enhanced TNF secretion (Figure 5a). Similar
observations were made in REH cells, which when chal-
lenged under isotonic conditions with low concentrations of
SM showed minimal (BV6 and birinapant) or no detectable
(LCL161) TNF release (Figure 5b). Again, hypertonicity sub-
stantially boosted SM-triggered TNF secretion (Figure 5b)
and was accompanied by enhanced SM-mediated cytotoxi-
city (Figures 3a–c). Mechanistically, this raised the question
whether hyperosmotic stress simply increased TNF release
initiated by SM via the non-canonical NFκB pathway or itself
triggered TNF production. Birinapant-induced non-canonical
NFκB activation (as seen by decline of p100) was not
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Figure 2 SMAC mimetic-induced cell death under hypertonic conditions involves TNF. (a and b) L929 cells were grown in medium supplemented with 75 mM NaCl and
challenged with the indicated concentrations of (a) BV6 and (b) LCL161 in the presence and absence of etanercept (400 μg/ml). (c) Cells were grown as above and treated with
the indicated concentrations of BV6 in the presence and absence of 75 μM necrostatin-1 (Nec-1). (d) L929 cells were grown in medium supplemented with 75 mM NaCl and
challenged with the indicated concentrations of birinapant in the presence and absence of the pan-caspase inhibitor zVAD-fmk (10 μM) and the RIPK3 inhibitor GSK’872 (2 μM).
Shown are data points and mean± S.E.M. from three independent experiments. Biri, birinapant
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enhanced under hypertonic conditions, potentially pointing to
an additional, hypertonicity-activated TNF-producing pathway
(Figure 5c). This was also supported by experiments that
demonstrated (a) increase of TNF levels in REH cells by NaCl
and birinapant alone (Figure 5d); (b) NaCl-triggered TNF
secretion in L929 cells without SM (Figure 5e) and (c)
increased TNF mRNA levels in REH cells cultured under
hypertonic conditions (Figure 5f).
TNF production under hypertonic conditions involves
p38 and NFAT5. Upregulation of osmoprotective genes is a
vitally important adaptive response to hyperosmotic stress
and is critically dependent on the transcription factor NFAT5
(also known as TonEBP) along with its hypertonicity-induced
activation through the mitogen-activated protein kinase
(MAPK) p38.23,24 Notably, NFAT5 also potently initiates
TNF transcription under hyperosmotic stress.25 We observed
hypertonicity-induced increase in TNF mRNA levels
(Figure 5f). The notion that SM cytotoxicity under hypertonic
conditions (Figures 1a–c and 3a–c) was associated with
higher TNF levels (Figures 5a and b) prompted us to
investigate whether the p38/NFAT5 axis could supplement
SM-triggered TNF secretion. Expectedly, increased NFAT5
levels (Figure 6a) and phosphorylation of p38 and ERK
(Figure 6b) were detectable in REH cells cultured under
hypertonic conditions. Birinapant treatment in the presence
and absence of NaCl significantly reduced cIAP2 levels,
but did not affect p38 and ERK activation. Previous reports
demonstrated that p38 inhibition blocked transcriptional
activity of NFAT5 and reduced NFAT5-mediated TNF
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Figure 3 Hypertonicity boosts SMAC mimetic-induced cell death in human ALL cells. (a–c) REH cells were treated with the indicated concentrations of the SMAC mimetics
(a) BV6, (b) LCL161 and (c) birinapant (Biri) in the presence and absence of 50 mM NaCl. (d–f) Top panel: REH cells were challenged with the indicated concentrations of NaCl in
the presence and absence of (a) 0.1 μM BV6, (b) 1 μM LCL161 or (c) 0.1 μM birinapant. Shown are data points and mean±S.E.M. from three independent experiments. Lower
panel: For each combination of SMAC mimetic plus NaCl, the corresponding combination index (CI) value was calculated. CI-valueso1 indicate a synergistic effect (see also the
Materials and Methods section). CI-values were calculated from mean values derived from three independent experiments. (g) Cells were treated as in (c), but 100 mM mannitol
was used to increase osmotic pressure. (h) KYM-1 cells were treated as in (b). Biri, birinapant
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production.24,26,27 Consequently, pharmacological inhibition
of p38 under hypertonic condition should attenuate SM
cytotoxicity as TNF upregulation via NFAT5 ceases. Assum-
ing that contribution of both, SM- and hypertonicity-induced
TNF production were responsible for SM cytotoxicity, we did
not expect a full-blown but partial rescue when blocking
only NFAT5-mediated TNF production. Indeed, the p38
inhibitors BIRB796, PH797804 and SB203580 significantly
diminished hypertonicity-granted increase in SM cytotoxicity
(Figures 6c–e) and (except for one outlier) decreased TNF
mRNA levels under hypertonic conditions (Figure 6f). Collec-
tively, these data suggested that triggering autocrine TNF
production via hypertonicity-induced p38/NFAT5 activation
was underlying synergistic cancer cell killing of SM/NaCl
combinations.
Hypertonicity-induced TNF release overcomes resis-
tance to SM monotherapy. Thus far, we demonstrated that
increased SM/NaCl cytotoxicity is linked to enhanced
autocrine TNF signaling (Figures 4a,b and 5b). As single
agents, SM efficacy also depends on autocrine TNF signaling
combined with a concomitant ‘death sensitizing’ function.
But most tumor entities fail to produce the critical effector
cytokine TNF upon SM exposure.5 We hypothesized that
hypertonicity-derived TNF could compensate for absent
autocrine TNF production in SM-resistant cells and reinstate
cytotoxicity of SM monotherapies. Indeed, human erythro-
leukemic TF-1 cells almost completely resisted even high-
dose treatments with the SM birinapant (Figure 7a), but
SM treatment still sensitized TF-1 cells to TNF generated
from nearby cells (paracrine TNF signaling). Challenging
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Figure 4 Hyperosmotic stress enhances SMAC mimetic-induced, TNF-mediated apoptosis in ALL cells. (a and b) REH cells were grown in medium supplemented with
50 mM NaCl and challenged with the indicated concentrations of (a) LCL161 and (b) birinapant (Biri) in the presence and absence of etanercept (400 μg/ml). Shown are data
points and mean±S.E.M. from three independent experiments. (c) REH cells were left untreated or challenged with 2.5 μM LCL161 or 2.5 μM birinapant with or without addition
of 50 mM NaCl. After incubation for 16 h, cells were analyzed by flow cytometry for positivity of 7-AAD and annexin-V. Data shown are representative of two experiments
performed. (d and e) REH cells were challenged with 0.3 μM BV6, LCL161 and birinapant with or without addition of 50 mM NaCl for 18 h. Caspase-8 and caspase-3/-7 activity
was assessed using the fluorogenic substrates (IETD)2-R110 and (DEVD)2-R110, respectively. Data points from three independent experiments are shown. A line connects
caspase activation under isotonic conditions with the corresponding value under hypertonic conditions (50 mM NaCl) for each experiment. (f) REH cells were treated with the
indicated concentrations of BV6, LCL161 and birinapant with or without addition of 50 mM NaCl and 50 μM zVAD-fmk. Shown are data points and mean± S.E.M. from three
independent experiments. Biri, birinapant
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co-cultures of ‘SM-resistant’ TF-1 and ‘SM-responsive’ REH
cells with birinapant under isotonic conditions revealed a
modest degree of cytotoxicity (Figure 7b), ranging expec-
tedly between REH (Figure 3c) and TF-1 cells (Figure 7a)
alone. In the presence of 50 mM NaCl, however, cyto-
toxicity of SM was drastically increased and apparently
TNF-dependent, as addition of etanercept almost completely
blocked cell death (Figure 7b). This indicates that SM/
NaCl-induced TNF release from nearby cells is sufficient to
kill SM-sensitized cells that fail to activate autocrine TNF
signaling. In line with this, supernatant harvested from SM/
NaCl-challenged REH cells efficiently killed SM-sensitized
TF-1 cells in a TNF-dependent manner (Figure 7c). Mechan-
istically, hypertonicity-induced TNF production can substitute
in SM-sensitized cancer cells for lack of SM-triggered TNF
release.
In sum, we demonstrate that hypertonicity-induced com-
plementary TNF secretion via the p38/NFAT5 axis enhances
SM-mediated cell death. Our work provides evidence that
activation of alternative endogenous auto- or paracrine TNF
sources can attenuate dependency on SM-induced TNF
release for efficient cancer cell killing (summarized in
Figure 8). Reducing the role of SM to TNF-sensitizing, but
not necessarily TNF-inducing agents, could perspectively
broaden the clinical application of SM-based therapies.
Discussion
In cancer cells, SM treatment ideally kills two birds with one
stone by simultaneous production of and sensitizing to the
effector molecule TNF. In most malignancies, however,
SM-induced autocrine TNF production is not functional.
Consequently, the response to SM monotherapy in preclinical
and clinical studies has thus far been poor.5,18 Nevertheless,
SM-mediated IAP depletion lowers the threshold for cell death
induction. Clinical trials currently evaluate whether this is
exploitable to enhance the anti-tumor activity of standard-of-
care cancer therapies.20
Alternatively, lack of SM-induced autocrine TNF secretion
could be compensated by activating complementary TNF-
producing pathways in cancer or other cell types in the tumor
environment. For example, TNF is upregulated in response to
bacterial and viral pathogen recognition by the innate immune
system. Intra-vesical instillation of Bacillus Calmette-Guérin
(BCG) to treat early stages of bladder cancer triggered
local inflammation and TNF release from recruited neutrophils.
In combination with SM, neutrophil-derived TNF potently
induced apoptosis.28 Additionally, oncolytic viruses syner-
gized with SM in a TNF-dependent manner to promote
tumor death in mouse models of breast cancer and glio-
blastoma.29,30 Cyto- and chemokine upregulation in response
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Figure 5 Hypertonicity and SMAC mimetics cooperate in autocrine TNF release. (a) L929 cells were cultured with or without addition of 75 mM NaCl and treated
with the indicated concentrations of BV6 and LCL161 for 18 h. Supernatants were collected and secretion of murine TNF was quantified using ELISA. (b) REH cells were
cultured with or without addition of 50 mM NaCl and treated with the indicated concentrations of BV6, LCL161 and birinapant (Biri) for 18 h. Secretion of human TNF in the
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birinapant in the presence and absence of 50 mM NaCl for the indicated periods of time. After washing and lysis, western blot analyses were performed with antibodies specific for
the indicated proteins. Detection of tubulin served as a loading control. (d) REH cells were challenged with 50 mM NaCl or 1.25 μM birinapant (Biri) for 6 h and subsequently
analyzed by western Blotting for the presence of the indicated proteins. (e) L929 cells were challenged with the indicated concentrations of NaCl for 18 h. Secretion of murine TNF
in the supernatant was quantified using ELISA. Data shown are representative of two experiments performed. (f) REH cells were challenged with 50 mM NaCl for the indicated
periods of time or left untreated. Tnf mRNA induction was analyzed by qPCR. Data points of three independent experiments together with mean±S.E.M. are shown. Biri,
birinapant
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to microbial invaders is stringently controlled and usually self-
limiting. Thus, innate immune stimuli could clinically be useful
to enhance cytotoxicity of SM through induction of a potent
yet safe ‘cytokine storm’. However, this approach might be
hampered in patients suffering from leukopenia during
standard-of-care chemotherapies or in patients treated with
immunosuppressive drugs in the course of transplantation.
Notably, exogenous stimuli such as hyperosmotic stress
can also initiate endogenous TNF production in cancer cells,26
mediated through binding of the transcription factor NFAT5
to the TNF promoter.25 Hypertonicity-induced TNF release
from cancer cells (and potentially also from cells in the
tumor environment) could therefore substitute for lacking
SM-induced TNF production, while still relying on the TNF-
sensitizing activity of SM. Our study strengthened this concept
by showing that hyperosmotic stress (a) initiated TNF release
in human and murine cells (Figure 5), (b) enhanced SM-
mediated cytotoxicity in a TNF-dependent manner (Figures
1–4 and 7) and (c) efficiently killed cancer cells in combination
with SM even when SM-induced TNF production was poor or
absent (Figures 5 and 7). Admittedly, hypertonicity-induced
increase in TNF levels might aggravate TNF-related side
effects. Cytokine release syndrome, for example, has been
reported as dose-limiting toxicity of systemic LCL161 admin-
istration in humans and is most likely attributable to SM-
induced, NFκB-mediated upregulation of pro-inflammatory
cytokines (including TNF).31 However, artificially establishing
(transient) hypertonic conditions in a narrowly defined area
such as the tumor environment could attenuate systemic
toxicity by spatially restricting TNF production and lowering
SM concentrations necessary for cancer cell elimination
(Figures 1g and h and 3d–f). At least in solid tumors, constant
55kDatubulin
130kDa
NFAT5
+NaClctrl
REH
55tubulin
p38
phospho-p38
40
40
40
40
ERK
phospho-ERK
*
*
*
NaCl
birinapant
- + - +
- - + +
-
-
- + - +
- - + +
- + - +
- - + +
15 min 45 min 90 minctr
REH
MW
[kDa]
cIAP2 70
M
TT
 in
te
ns
ity
 [%
 o
f c
tr
]
0
25
50
75
100
Biri
BIRB796
-
-
+
+
+
-
+50mM NaClmediumREH
M
TT
 in
te
ns
ity
 [%
 o
f c
tr
]
0
25
50
75
100
Biri
PH797804
-
-
+
+
+
-
+50mM NaClmediumREH
M
TT
 in
te
ns
ity
 [%
 o
f c
tr
]
0
25
50
75
100
Biri
SB203580
-
-
+
+
+
-
+50mM NaClmediumREH
0
0.25
0.50
0.75
1.00
TN
F 
m
R
N
A 
[fo
ld
 in
du
ct
io
n] 2.00
REH
BIRB796 PH797804 SB203580control
50mM NaCl
Figure 6 TNF production under hypertonic conditions involves p38 and NFAT5. (a) REH cells were cultured in the presence and absence of 50 mM NaCl for 16 h. Cells were
washed, lysed and subsequently analyzed using western blotting with antibodies specific for the indicated proteins. (b) REH cells were challenged with 1.25 μM birinapant in the
presence and absence of 50 mM NaCl for the indicated periods of time. Subsequently, cells were lysed and analyzed by western blot for the indicated proteins. The asterisks (*) in
the phospho-p38, ERK and phospho-ERK blots indicate a defect in the CCD sensor of the western Blot imaging system. All samples were run on the same gel, no gels were
sliced. (c–e) REH cells were challenged with 2.5 μM birinapant under isotonic (medium) or hypertonic (+50 mM NaCl) conditions in the presence and absence of the p38
inhibitors BIRB796, PH797804 and SB203580 (5 μM). Shown are data points and mean± S.E.M. from four independent experiments. (f) REH cells were challenged with 50 mM
NaCl for 210 min in the presence and absence of the p38 inhibitors BIRB796, PH797804 and SB203580 (5 μM). TnfmRNA induction was analyzed by qPCR. Data points of three
independent experiments are shown. Biri, birinapant
Hypertonicity boosts cytotoxicity of SMAC mimetics
S Bittner et al
7
Cell Death and Disease
release of non-diffusible osmolytes from implantable devices
(technically comparable to carmustine-releasing polymer
implant wafers in malignant glioma treatment) could establish
local osmotic pressure gradients and help to exert maximum
SM cytotoxicity to the tumor while reducing damage in
adjacent healthy tissues.
Interestingly, our results also highlight a new facet of p38 in
SM cytotoxicity. A recent study elegantly demonstrated that
inhibition of p38 or its downstream kinase MK2 enhanced the
anti-leukemic activity of SM, essentially by increasing SM-
mediated TNF production.32 Hyperosmotic stress activates
p38,33 raising the possibility of reduced SM cytotoxicity (due to
lower TNF production) under hypertonic conditions. Our
results, however, indicate the opposite. Although p38 activa-
tion was clearly detectable under hypertonic conditions
(Figure 6b), SM treatment resulted in higher TNF levels
compared with isotonic controls (Figures 5a and b). At a first
glance, this observation seems to contradict the aforemen-
tioned study. Under hypertonic conditions, p38-dependent
activation of the transcription factor NFAT5 not only upregu-
lates osmoprotective genes23,24,33 but also TNF.25 Several
studies reported reduced hypertonicity-induced TNF produc-
tion upon p38 and/or NFAT5 inhibition.26,27,34 In line with this,
we observed lower Tnf mRNA levels and (Figure 6f) reduced
SM cytotoxicity under hypertonic conditions in the presence of
p38 inhibitors (Figures 6c–e). Whether p38 activation
enhances or attenuates SM cytotoxicity might therefore
depend on the pathway utilized to supply the key effector
molecule TNF. Whereas under isotonic conditions inhibition of
p38 boosted TNF secretion by enhancing SM-induced JNK1/2
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and ERK1/2 phosphorylation,32 p38 inhibition under hyper-
tonic conditions blunted NFAT5 activation and transcription
of its target gene TNF.26,27,34 Activation of an additional
endogenous TNF-producing pathway might be of special
relevance in tumor cells that respond poorly to SM alone.
In sum, our data revealed that hypertonicity enhanced
SM-mediated cell death by complementary TNF secretion.
Activation of an alternative TNF source attenuated the
dependency on SM-induced TNF release for efficient cancer
cell killing (summarized in Figure 8). The tumor environment
may therefore not necessarily be an unchangeable adverse
determinant in cancer therapy. At least in some cancer
entities, physico-chemical modulation of the tumor environ-
ment could be exploited to enhance treatment efficacy and
broaden clinical application of SM-based therapies.
Materials and Methods
Cell lines, antibodies and reagents. REH (#ACC-22), TF-1 (#ACC334)
and L929 (#ACC-2) cells were obtained from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany), KYM-1 cells were
kindly provided by Harald Wajant (University of Wuerzburg). All cell lines were
grown RPMI 1640 medium (PAN Biotech, Aidenbach, Germany) supplemented with
10% (v/v) fetal calf serum (Sigma, Steinheim, Germany). TF-1 cells were
additionally supplemented with 5 ng/ml human granulocyte–macrophage colony-
stimulating factor (Immunotools, Friesoythe, Germany). Antibodies used in the
study: TNF #3707, p38 #9212, phospho-p38 #9211, ERK #4695, phospho-ERK
#4370 (Cell Signaling, Beverly, MA, USA); tubulin #MS-581: Dunnlab (Asbach,
Germany); NFAT5 #PA1-023: Thermo Fisher Scientific (Waltham, MA, USA).
Chemicals: MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide):
Biomol (Hamburg, Germany); zVAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-
(Omethyl)-fluoromethylketone): Bachem (Bubendorf, Switzerland); BIRB796,
PH797804, SB203580, BV6, LCL161 and birinapant: Selleck Chemicals (Houston,
TX, USA). Necrostatin-1 (Nec-1): Stress-Marq (Victoria, Canada); Etanercept was
obtained from Pfizer (Berlin, Germany).
MTT-based cell viability assay. L929 (2 × 104 cells/well), REH cells
(7 × 104 cells/well) and TF-1 cells (7 × 104 cells/well) were seeded in 96-well plates
and challenged with the indicated concentrations of SM in triplicates (technical
replicates). For co-culture assays, 1:1 mixtures of TF-1 and REH cells (5 × 104 cells
of each cell line/well) were seeded in 96-well plates and stimulated as above. Cell
viability was determined 18 h after stimulation using MTT staining (2 h at 37 °C).
Staining intensity was measured at 595 nm and the mean was calculated from the
technical replicates of each experiment. The mean value for untreated controls
was set to 100%. For any other condition, the MTT staining intensity is given
relative to the corresponding untreated group (% of control). Data points shown are
mean values (calculated from 3 technical replicates) of independent experiments
(n≥ 3).
Western blot analysis. Cells were harvested, spun down and were directly
dissolved in 4 × Laemmli sample buffer (8% (w/v) SDS, 0.1 M dithiothreitol, 40% (v/
v) glycerol, 0.2 M Tris, pH 8.0) supplemented with phosphatase inhibitor cocktails-I
and -II (Sigma). Samples were sonicated and boiled for 5 min at 96 °C before
proteins were separated by SDS-PAGE and transferred to PVDF membranes. To
block non-specific binding sites, membranes were incubated in TBS containing
0.1% (v/v) Tween 20 and 5% (w/v) dry milk before primary antibodies of the
specificity of interest were added. Antigen–antibody complexes were visualized
using horseradish peroxidase-conjugated secondary antibodies (Dako, Hamburg,
Germany) and ECL technology (Pierce, Rockford, IL, USA).
Calculation of CI. CI-values were calculated with the freely available software
CompuSyn version 1.0 using the median effect/combination index isobologram
method.12 In this model, CI-valueso1 are considered to be synergistic and CI41
indicate antagonistic effects. Strength of synergism can be further graded: o0.1
very strong synergism, 0.1–0.3 strong synergism, 0.3–0.7 synergism, 0.7–0.85
moderate synergism, 0.85–0.9 slight synergism, 0.9–1.1 no synergism but nearly
additive effects.
Enzyme-linked immunosorbent assay. For measuring TNF secretion,
L929 cells (2 × 104/well) or REH cells (1 × 106/well) were seeded in 96-well tissue
culture plates and cultured overnight. The next day, cells were challenged with SM
in the presence and absence of NaCl. The supernatant was collected and TNF was
quantified using an enzyme-linked immunosorbent assay (BD Biosciences,
Heidelberg, Germany). All groups were analyzed as triplicates (technical replicates).
Caspase activity assays. Caspase activity was measured using the
caspase-3/-7 and caspase-8 activity kit (AAT Bioquest, Sunnyvale, CA, USA)
according to the manufacturer’s instructions. Emitted fluorescence was quantified
using a Victor3 Multilabel Reader (Perkin Elmer, Waltham, MA, USA).
qPCR. qPCR was essentially performed as described previously.35 In brief, total
RNA was isolated using the Qiagen RNeasy mini kit (Valencia, CA, USA) according
to the manufacturer’s instructions. Two micrograms of total RNA were transcribed
into complementary DNA using the high-capacity cDNA reverse transcription kit
(Applied Biosystems, Carlsbad, CA, USA). Tnf mRNA levels were quantified using
the TaqMan human Tnf (Hs00174128_m1) gene expression assay (Applied
Biosystems) and an ABI Prism 7900 sequence detector (Applied Biosystems). qRT-
PCR reactions were performed in duplicates for each sample of an experiment and
normalized to the housekeeping gene Hprt1 (Hs02800695_m1). mRNA levels were
calculated using the SDS 2.1 software (Applied Biosystems).
Flow cytometry. Cell death was assessed by Annexin-V and 7-AAD staining.
In brief, REH cells were challenged with 2.5 μM LCL161 and birinapant for
16 h in the presence and absence of 50 mM NaCl. Afterwards, cells were stained
with 7-AAD and Annexin-V (4 °C for 15 min in the dark) and analyzed imme-
diately using a FACSCanto flow cytometer (BD Biosciences) following standard
procedures.
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